Login to Your Account

Another 'BiTE' as Micromet Inks Potential €320M Sanofi Alliance

By Jennifer Boggs

Friday, October 30, 2009

With buzz growing about Micromet Inc.'s BiTE antibody blinatumomab (MT103) ahead of the upcoming American Society of Hematology meeting, the Bethesda, Md.-based firm scored an early stage deal with Sanofi-Aventis SA to develop another BiTE compound. (BioWorld Today)


To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription